DR. JOHN LUTHER DOLAN, M.D.
Medical Practice at Captain Dr, Oakland, CA

License number
California A23389
Category
Medical Practice
Type
Specialist
Address
Address
7 Captain Dr #310, Oakland, CA 94608
Phone
(541) 301-7741

Professional information

John L Dolan Photo 1

Dr. John L Dolan, Emeryville CA - MD (Doctor of Medicine)

Specialties:
Emergency Medicine
Address:
7 Captain Dr, Emeryville 94608
(541) 301-7741 (Phone)
Certifications:
Emergency Medicine, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of California At San Francisco


John Dolan Photo 2

2-Amino-7,8-Dihydro-6H-Pyrido[4,3-D]Pyrimidin-5-Ones

US Patent:
2010000, Jan 7, 2010
Filed:
Jul 31, 2009
Appl. No.:
12/462302
Inventors:
Cynthia M. Shafer - Emeryville CA, US
Christopher McBride - Emeryville CA, US
Brandon M. Doughan - Emeryville CA, US
Barry H. Levine - Emeryville CA, US
Yi Xia - Emeryville CA, US
Maureen McKenna - Emeryville CA, US
Kris Mendenhall - Emeryville CA, US
Yasheen Zhou - Emeryville CA, US
Baoqing Gong - Emeryville CA, US
Dan Gu - Emeryville CA, US
John Dolan - Emeryville CA, US
John Tulinsky - Emeryville CA, US
Kristin Brinner - Emeryville CA, US
Zhenhai Gao - Emeryville CA, US
Daniel Poon - Emeryville CA, US
Paul Barsanti - Emeryville CA, US
Xiaodong Lin - Emeryville CA, US
Abran Costales - Emeryville CA, US
Alice Rico - Emeryville CA, US
Nathan Brammeier - Emeryville CA, US
Teresa Pick - Emeryville CA, US
Paul A. Renhowe - Emeryville CA, US
International Classification:
C07D 471/04, A61K 31/5377, A61K 31/497, A61K 31/519
US Classification:
5142342, 51425505, 51426411, 544117, 544279, 546243
Abstract:
Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.